Physician profile
Mukemil Abdella
NPI 1871603381
$4,924.67
in general payments reported to CMS, 2019-2025
28 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $235 · 2021: $817 · 2022: $1,200 · 2023: $984 · 2024: $860 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,265 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,264.70 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $767.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $661.69 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $592.94 | 2021-2025 | Farxiga, Airsupra |
| Pfizer INC. | $394.39 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $311.84 | 2021-2025 | |
| Abbott Laboratories | $301.44 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Horizon Therapeutics Plc | $249.56 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $233.69 | 2019-2025 | Jardiance, Zepbound, Kisunla |
| Amgen INC. | $216.69 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $186.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $182.13 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.05 | 2021-2023 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $105.65 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $100.91 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $74.29 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $59.99 | 2022 | |
| Gilead Sciences, INC. | $53.45 | 2021-2023 | |
| Axsome Therapeutics, INC. | $51.95 | 2023 | Sunosi |
| Vanda Pharmaceuticals INC. | $50.69 | 2022 | |
| Exact Sciences Corporation | $32.31 | 2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $25.44 | 2020 | |
| Inspire Medical Systems, INC. | $25.35 | 2024 | Inspire |
| Xeris Pharmaceuticals, INC. | $22.25 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.15 | 2022 | |
| Seqirus USA INC | $20.83 | 2024 | Flucelvax, Fluad |
| Biohaven Pharmaceuticals, INC. | $15.61 | 2021 | |
| Merck Sharp & Dohme LLC | $15.33 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukemil Abdella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.